/
ADXN
$6.00-$0.07 (-1.15%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.7M
1M shares
52-week range
$5.41 – $12.05
9% from low
Exchange
NASDAQ
ADRC
Borrow rate
10.96%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-212.00
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.0M | $2.8M | $3.6M | $2.9M | $1.4M | $1.6M | $404.1K | $30.0K |
| Cost of revenue | $144.2K | $230.1K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $5.9M | $2.5M | $3.6M | $2.9M | $1.4M | $1.6M | $404.1K | $30.0K |
| Gross margin | 97.6% | 91.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $2.4M | $12.5M | $10.4M | $9.0M | $7.9M | $942.7K | $435.2K | $190.2K |
| Operating income | −$1.4M | −$14.6M | −$12.2M | −$15.5M | −$10.5M | −$2.2M | −$2.8M | −$2.8M |
| EBITDA | −$1.5M | −$14.3M | −$12.4M | −$14.9M | −$10.5M | −$2.2M | −$4.6M | −$6.8M |
| Net income | −$1.6M | −$14.8M | −$12.9M | −$15.4M | −$20.8M | −$10.6M | $7.1M | −$6.7M |
| Net margin | -27.2% | -535.0% | -355.9% | -526.4% | -1462.6% | -654.5% | 1746.0% | -22448.4% |
| EPS (diluted) | -8.47 | -67.20 | -57.60 | -54.00 | -55.20 | -16.80 | 8.40 | -6.88 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-4.74 | $-4.74–$-4.74 | 2 |
| 2027 | $6M | $-3.24 | $-3.24–$-3.24 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.42
Price
$6.00
Implied downside
-76%
Peer comparison
Addex Therapeutics Ltd American Depositary Shares
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
www.addextherapeutics.com- Employees
- 3
- IPO / List date
- Jan 29, 2020
Held by traders on TradeandTell
No one on the platform currently holds ADXN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ADXN as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-10-23 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded ADXN yet.
